Benzinga's Small Cap Movers for Thursday January 3, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of BG Medicine (NASDAQ: BGMD), the Waltham, MA company focused on the development and commercialization of novel cardiovascular diagnostics, rose 18% Thursday on 5 times average volume.
BG Medicine announced Wednesday that the first automated version of the BGM Galectin-3 blood test has obtained a CE Mark, an important step in the company's commercial strategy. The BGM Galectin-3 test will be distributed through bioMerieux's VIDAS immunoassay platform which includes about 27,000 installed instruments worldwide. bioMerieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMerieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.
BG Medicine closed at $2.75 on Thursday.
Real Goods Solar
Shares of Real Goods Solar (NASDAQ: RSOL), the Louisville, CO provider of turnkey solar energy solutions, rose 18% Thursday on 4 times average volume.
Real Goods Solar shares traded higher as part of a strong solar group, helped by SunPower's (NASDAQ: SPWR) $2.5 billion deal with Warren Buffett's MidAmerican Energy.
Real Goods Solar closed at $0.99 on Thursday.
Shares of Zalicus (NASDAQ: ZLCS), the Cambridge, MA biopharmaceutical company, rose 15% Thursday on 3.5 times average volume.
Zalicus announced Thursday that it has initiated the second of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type (Cav2.2) calcium channel blocker for the potential treatment of chronic neuropathic pain. The Company also provided an overview of 2012 accomplishments.
Zalicus closed at $0.76 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.